OcuSciences
was formed to commercialize a technology that can rapidly and non-invasively
detect and monitor retinal metabolic dysfunction at an earlier stage than currently possible and
before irreversible cell damage occurs due to a variety of diseases, including diabetes and macular degeneration. OcuSciences plans to
establish RMATM
as a standard tool for detecting and monitoring retinal metabolic dysfunction in primary eye care practices throughout the world.
OcuSciences
will focus first on early detection of diabetes and pre-diabetes and
the monitoring of disease progression due to retinal cell
damage. Currently, most adults do not get screened regularly for
diabetes due to the cumbersome nature of existing screening methods, as
they are invasive, require fasting and involve blood draws. Thus, there
are over 8 million undiagnosed diabetics in the US (26.5M total) and
79 million pre-diabetics. As most adults visit a primary eye care practice for reading glasses starting at the
age of 40, primary eye care is a perfect initial venue for screening
for diabetes and monitoring disease progression.
|
